Andrew H. Wei

42.9k total citations · 10 hit papers
258 papers, 11.7k citations indexed

About

Andrew H. Wei is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Andrew H. Wei has authored 258 papers receiving a total of 11.7k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Hematology, 112 papers in Molecular Biology and 68 papers in Genetics. Recurrent topics in Andrew H. Wei's work include Acute Myeloid Leukemia Research (181 papers), Histone Deacetylase Inhibitors Research (51 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Andrew H. Wei is often cited by papers focused on Acute Myeloid Leukemia Research (181 papers), Histone Deacetylase Inhibitors Research (51 papers) and Chronic Myeloid Leukemia Treatments (44 papers). Andrew H. Wei collaborates with scholars based in Australia, United States and Germany. Andrew H. Wei's co-authors include David C.S. Huang, Simon N. Willis, Jerry M. Adams, Courtney D. DiNardo, Jamie I. Fletcher, Andrew W. Roberts, Catherine L. Day, Peter M. Colman, Marina Konopleva and Brenda Chyla and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Andrew H. Wei

241 papers receiving 11.6k citations

Hit Papers

Differential Targeting of Prosurvival Bcl-2 Proteins by T... 2005 2026 2012 2019 2005 2018 2005 2006 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function
    2005 1.5k citations Andrew H. Wei, David C.S. Huang et al. profile →
  2. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
    2018 1.2k citations Courtney D. DiNardo, Keith W. Pratz et al. Blood profile →
  3. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-x L , but not Bcl-2, until displaced by BH3-only proteins
    2005 1.0k citations Andrew H. Wei, David C.S. Huang et al. profile →
  4. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
    2006 1.0k citations Andrew H. Wei, Peter E. Czabotar et al. profile →
  5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
    2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. profile →
  6. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
    2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →
  7. MDM2 inhibition: an important step forward in cancer therapy
    2020 276 citations Marina Konopleva, Naval Daver et al. profile →
  8. Acute myeloid leukaemia
    2023 193 citations Courtney D. DiNardo, Sylvie Freeman et al. profile →
  9. Towards precision medicine for AML
    2021 174 citations Andrew H. Wei et al. profile →
  10. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
    2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew H. Wei Australia 43 7.4k 5.3k 2.8k 1.7k 1.6k 258 11.7k
Michael Lübbert Germany 60 7.4k 1.0× 7.2k 1.4× 2.0k 0.7× 2.2k 1.3× 1.3k 0.8× 297 12.7k
Roland B. Walter United States 53 3.7k 0.5× 6.7k 1.3× 3.2k 1.1× 1.4k 0.9× 1.6k 1.0× 365 11.0k
Scott C. Kogan United States 49 7.8k 1.0× 3.9k 0.7× 1.8k 0.6× 960 0.6× 1.2k 0.8× 140 10.7k
Gert J. Ossenkoppele Netherlands 53 4.4k 0.6× 8.6k 1.6× 2.8k 1.0× 2.8k 1.7× 1.9k 1.2× 279 12.3k
Hubert Serve Germany 59 8.5k 1.1× 6.8k 1.3× 3.1k 1.1× 2.6k 1.6× 1.7k 1.1× 299 15.5k
Selina M. Luger United States 47 2.9k 0.4× 5.4k 1.0× 2.9k 1.0× 1.1k 0.7× 1.3k 0.8× 304 9.7k
Craig T. Jordan United States 62 10.2k 1.4× 6.6k 1.3× 4.5k 1.6× 1.9k 1.2× 3.0k 1.9× 237 17.3k
Jianxiang Wang China 42 3.8k 0.5× 2.8k 0.5× 2.1k 0.8× 1.1k 0.7× 1.1k 0.7× 415 7.7k
Jesús María Hernández‐Rivas Spain 49 3.5k 0.5× 4.2k 0.8× 2.2k 0.8× 2.6k 1.5× 1.5k 0.9× 318 9.2k
Carsten Müller‐Tidow Germany 64 11.4k 1.5× 5.3k 1.0× 4.3k 1.5× 1.8k 1.1× 2.2k 1.4× 492 18.0k

Countries citing papers authored by Andrew H. Wei

Since Specialization
Citations

This map shows the geographic impact of Andrew H. Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew H. Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew H. Wei more than expected).

Fields of papers citing papers by Andrew H. Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew H. Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew H. Wei. The network helps show where Andrew H. Wei may publish in the future.

Co-authorship network of co-authors of Andrew H. Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew H. Wei. A scholar is included among the top collaborators of Andrew H. Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew H. Wei. Andrew H. Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wei, Andrew H., Harry Iland, Courtney D. DiNardo, & John Reynolds. (2025). Measurable residual disease intervention in AML: a new therapeutic horizon. Blood. 147(1). 13–23.
2.
Kueh, Andrew J., Martin Pál, Lin Tai, et al.. (2025). Transcriptomic changes including p53 dysregulation prime DNMT3A mutant cells for transformation. EMBO Reports. 26(11). 2855–2882.
3.
Chua, Chong Chyn, Sun Loo, Chun Yew Fong, et al.. (2025). Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT). Blood Advances. 9(8). 1827–1835. 4 indexed citations
4.
Peng, Hongke, Jafar S. Jabbari, Luyi Tian, et al.. (2025). Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genes. Genome Research. 35(4). 942–955. 1 indexed citations
5.
Tiong, Ing Soo, Devendra Hiwase, Ashish Bajel, et al.. (2024). Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology. 42(18). 2161–2173. 18 indexed citations
6.
Brown, Fiona C., Richard W. Birkinshaw, Chong Chyn Chua, et al.. (2024). Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia. Blood Advances. 9(1). 127–131. 7 indexed citations
7.
Wei, Andrew H., Sun Loo, & Naval Daver. (2024). How I treat patients with AML using azacitidine and venetoclax. Blood. 145(12). 1237–1250. 15 indexed citations
8.
Ravandi, Farhad, Jacqueline Cloos, Francesco Buccisano, et al.. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel. American Journal of Hematology. 98(12). 1847–1855. 10 indexed citations
9.
Shah, Mithun Vinod, Rakchha Chhetri, Chung Hoow Kok, et al.. (2022). Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms. American Journal of Hematology. 97(8). 1013–1022. 8 indexed citations
10.
Daver, Naval, Abhishek Maiti, Tapan M. Kadia, et al.. (2022). TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discovery. 12(11). 2516–2529. 83 indexed citations
11.
Konopleva, Marina, Michael J. Thirman, Keith W. Pratz, et al.. (2022). Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clinical Cancer Research. 28(13). 2744–2752. 59 indexed citations
12.
Loo, Sun, Richard Dillon, Adam Ivey, et al.. (2022). Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 140(22). 2407–2411. 42 indexed citations
13.
Shallis, Rory M., Naval Daver, Jessica K. Altman, et al.. (2022). TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 129(2). 175–180. 11 indexed citations
14.
Pollyea, Daniel A., Keith W. Pratz, Andrew H. Wei, et al.. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research. 28(24). 5272–5279. 75 indexed citations
15.
Bjelosevic, Stefan, Andrea Newbold, Jennifer R. Devlin, et al.. (2021). Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia. Cancer Discovery. 11(6). 1582–1599. 50 indexed citations
16.
17.
18.
Wei, Andrew H., Stephen A. Strickland, Jing-Zhou Hou, et al.. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology. 37(15). 1277–1284. 456 indexed citations breakdown →
19.
Wei, Andrew H., Jacqueline S. Garcia, Uma Borate, et al.. (2019). A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 568–568. 39 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Lübbert Breakdown of academic impact, for papers by Roland B. Walter Breakdown of academic impact, for papers by Scott C. Kogan Breakdown of academic impact, for papers by Gert J. Ossenkoppele Breakdown of academic impact, for papers by Hubert Serve Breakdown of academic impact, for papers by Selina M. Luger Breakdown of academic impact, for papers by Craig T. Jordan Breakdown of academic impact, for papers by Jianxiang Wang Breakdown of academic impact, for papers by Jesús María Hernández‐Rivas Breakdown of academic impact, for papers by Carsten Müller‐Tidow
Rankless by CCL
2026